The Economic Burden of Acute Myeloid Leukemia in Iran

2021 ◽  
Author(s):  
Vahid Alipour ◽  
Soroush Rad ◽  
Fateme Mezginejad ◽  
Zeinab Dolatshahi ◽  
Reza Jahangiri ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Economic Burden ◽  
Myeloid Leukemia ◽  
Indirect Costs ◽  
Direct Costs ◽  
Great Opportunity ◽  
The Third ◽  
Productivity Losses ◽  
The Cost ◽  
Acute Myeloid

Abstract BackgroundCancer imposes a significant economic burden on the health system and society. Acute myeloid leukemia (AML) is the third deadliest leukemia and is one of the leading health problems worldwide. The present study aims to estimate the economic burden of AML in Iran for 2020.MethodsIn this study, we estimated a prevalence-based on the cost-of-illness of the AML in Iran. A societal perspective was considered, in which the direct costs and productivity losses with the adoption of the human capital approach in the AML cases were estimated for 2020. Moreover, in the present study, several resources including national cancer registry reports, hospital records, occupational data, and interviews with experts were cited.ResultApproximately 98% of patients with AML received induction therapy. The AML economic burden was $ 33243107.39. Indirect costs accounted for 60% of this amount, and direct medical costs made up for 19% of this estimated economic burden.ConclusionThe economic burden of AML in Iran is very significant and due to the increasing prevalence of this disease, it is expected to increase more gradually. Awareness of the costs associated with this disease provides a great opportunity for policymakers and managers of the health systems to improve resource allocation efficiently.

Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemia

2007 ◽  
Vol 31 (4) ◽  
pp. 531-539 ◽  
Author(s):  
Michael Fiegl ◽  
Matthias Juergens ◽  
Wolfgang Hiddemann ◽  
Jan Braess
Keyword(s):  
Acute Myeloid Leukemia ◽  
Zoledronic Acid ◽  
Cytotoxic Activity ◽  
Myeloid Leukemia ◽  
Third Generation ◽  
The Third ◽  
Acute Myeloid

AML-117: The Economic Burden of Relapse in Acute Myeloid Leukemia (AML): A Retrospective Analysis of US Commercial and Medicare Claims

2020 ◽  
Vol 20 ◽  
pp. S181
Author(s):  
Ashley Tabah ◽  
David Huggar ◽  
Brenna L. Brady ◽  
Krutika Jariwala-Parikh ◽  
Krystal Huey ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Retrospective Analysis ◽  
Economic Burden ◽  
Myeloid Leukemia ◽  
Medicare Claims ◽  
Acute Myeloid

scholarly journals Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States

2018 ◽  
Vol 71 ◽  
pp. 27-33 ◽  
Author(s):  
Jill A. Bell ◽  
Aaron Galaznik ◽  
Eileen Farrelly ◽  
Marlo Blazer ◽  
Sharanya Murty ◽  
...  
Keyword(s):  
United States ◽  
Acute Myeloid Leukemia ◽  
Elderly Patients ◽  
Economic Burden ◽  
Myeloid Leukemia ◽  
Clinical Care ◽  
The United States ◽  
Routine Clinical Care ◽  
Acute Myeloid

CD19 Expression in t(8;21)-Negative Acute Myeloid Leukemia Is Not Restricted to Cytogenetically Aberrant Populations.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4128-4128
Author(s):  
Jawad Francis ◽  
Avinash Dharmadhikari ◽  
Sheila N.J. Sait ◽  
George Deeb ◽  
Paul K. Wallace ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Normal Karyotype ◽  
Leukemic Cells ◽  
Aberrant Expression ◽  
The Third ◽  
Signal Pattern ◽  
First Case ◽  
Cd19 Expression ◽  
Acute Myeloid

Abstract Abstract 4128 Aberrant expression of the B lymphoid marker, CD19, in acute myeloid leukemia (AML) has frequently been associated with t(8;21)(q22;q22). However, AML cases lacking this translocation may occasionally express CD19. We identified eight such cases at Roswell Park Cancer Institute. Three of these cases had noticeable CD19-positive leukemic subsets with the following karyotypic abnormalities. The first case had monosomy X in 6 cells and normal karyotype in 14, the second case had trisomy 22 in 19 cells and normal karyotype in one, and the third case had monosomy 7 in 18 cells and trisomy 18 in two. We therefore asked if CD19 expression is restricted to the karyotypically abnormal leukemic cells. Bone marrow cells were sorted according to the specific immunophenotype. First, a generous mononuclear sorting region was drawn in the bivariate display of forward versus side scatter to exclude debris and aggregates. Next, the CD45-negative to CD45-dim, CD19-positive and CD34-positive leukemic cells were sorted. Fluorescent in situ hybridization (FISH) studies were carried out on the sorted samples using the following commercially available probes: the Centromere enumeration probe CEP X (SpectrumGreen) in the first case; the locus specific BCR (22q11) (SpectrumGreen)/ABL1 (9q34) (SpectrumOrange) dual color, dual fusion, translocation probe in the second, and the locus specific D7S486 (7q31) SpectrumOrange/CEP 7 SpectrumGreen probe in the third. A total of 200 nuclei were assessed in each case. The results are displayed in the Table below. There were no significant differences in the signal pattern between the CD19-positive and CD19-negative leukemic populations. These results indicate that aberrant CD19 expression in t(8;21)-negative AML is not restricted to leukemic cells that harbor specific karyotypic abnormalities. Table FISH results based on CD19 expression Case # Probe Signal Pattern CD19-positive CD19-negative 1 CEP X 1 Green (-X) 20/200 30/200 2 BCR/ABL 3 Green/2 Orange (+22) 163/200 170/200 3 CEP 7 1 Green/1 Orange (-7) 200/200 200/200 Disclosures: No relevant conflicts of interest to declare.

The Economic Costs of Acute Myeloid Leukemia in Sweden

1994 ◽  
Vol 10 (4) ◽  
pp. 683-694 ◽  
Author(s):  
Gunnel Ragnarson Tennvall ◽  
Ulf Persson ◽  
Bo Nilsson
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Treatment Options ◽  
Cost Savings ◽  
Indirect Costs ◽  
Premature Mortality ◽  
Economic Costs ◽  
Potential Cost ◽  
New Treatment ◽  
Acute Myeloid

AbstractThe direct and indirect costs of acute myeloid leukemia were estimated for Sweden in 1989. The calculated total cost was SEK 460 million. Nearly half of the costs, or 1.7 million per patient diagnosed, were indirect costs due to premature mortality. Direct costs of relapses and indirect costs of mortality represent costs due to the absence of completely curable therapy. They also represent potential cost savings that could be ootained after introduction of new treatment options in the future.

Direct burden of oncologic disease in a socialized health care system: Using acute myeloid leukemia as an example.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e12040-e12040
Author(s):  
Marta Isabel De Correia Pereira ◽  
Emilia Cortesao ◽  
Ana Espadana ◽  
Gilberto P Marques ◽  
Catarina Geraldes ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Healthcare System ◽  
Myeloid Leukemia ◽  
Direct Costs ◽  
Average Hospital ◽  
Major Complications ◽  
Number Of Patients ◽  
Oncologic Patients ◽  
The Impact ◽  
Acute Myeloid

e12040 Background: Portugal has a socialized national healthcare system (NHS), rated 12th overall by WHO (2000), that exempts oncologic patients from paying the direct costs of treatment. It has a per capita Gross Domestic Product of $22 699 (International Monetary Fund, 2011), less than 50% of the US, and was severely affected by the international Financial Crisis, requiring a bail-out; in this scenario, the state budget for health for 2012 is approximately $9900 million. Adult acute myeloid leukemia (AML) is a relatively rare cancer, with standardized non-surgical inpatient treatment protocols (outside clinical trials) that are subject to little variation between centers and over time, characteristics that make it an ideal example to evaluate the impact of oncologic disease on a socialized healthcare system. Methods: We reviewed all new diagnoses of AML over a five-year period (2006 to 2010) in one of the 7 national centers that treat adult AML, to estimate the yearly expenditure with direct costs. Results: Over the period considered, 192 new adult cases were diagnosed (38.4 cases per year, 47% male), with a median age of 63 years; 43.8% were 65 or over. The 2009 National Directive assumes the daily cost of one hospitalization for uncomplicated adult “acute leukemia” [sic] to be $1250, with an average hospital stay of 12.2 days, amounting to $15 250; minor complications increase this to $2400 and 19.5 days, and major complications to $6 480 times 25 days, or $162 000. An allogeneic HSC transplant (allo-HSC) costs $9 605 daily, over 35.5 days, or $340 800. Assuming induction and one cycle of consolidation in under-65 cases, this Hospital would spend between $700 000 (no complications in either cycle) and $7 million (all cases with major complications in both cycles) on new cases per year. Additional cycles and allo-HSC push the estimate towards $1-10 million. Conclusions: While chronic metabolic, cardiovascular and respiratory diseases consume the bulk of resources, the burden of oncologic disease on a socialized NHS is marked. AML ideally exemplifies how a small number of patients can consume vast resources: as this estimate shows, Portugal could expect to spend $7-70 million of the 2012 health budget on new cases of AML alone.

A Novel and Cytogenetically Cryptic t(7;21)(q36.1;q22) Disrupting RUNX1 in Acute Myeloid Leukemia

2018 ◽  
Vol 156 (3) ◽  
pp. 140-143 ◽  
Author(s):  
Adriana Zámečníkova ◽  
Soad Al Bahar
Keyword(s):  
Acute Myeloid Leukemia ◽  
Transcription Factor ◽  
Myeloid Leukemia ◽  
De Novo ◽  
Hematologic Malignancies ◽  
Transcription Factor Gene ◽  
Factor Gene ◽  
The Third ◽  
Partner Gene ◽  
Acute Myeloid

Translocations involving the RUNX1 transcription factor gene are frequently identified in leukemia patients, but the partner genes have been characterized in only about half of these cases. We report here a novel RUNX1 partner gene, KMT2C (MLL3), in a patient with de novo acute myeloid leukemia, having a novel and cytogenetically cryptic t(7;21)(q36.1;q22) leading to disruption of RUNX1 and KMT2C. This is the third cryptic RUNX1 rearrangement in myeloid and the fourth in hematologic malignancies.

The economic burden of depression in Sweden from 1997 to 2005

2007 ◽  
Vol 22 (3) ◽  
pp. 146-152 ◽  
Author(s):  
Patrik Sobocki ◽  
Ingrid Lekander ◽  
Fredrik Borgström ◽  
Oskar Ström ◽  
Bo Runeson
Keyword(s):  
Sick Leave ◽  
Economic Burden ◽  
Early Retirement ◽  
Indirect Costs ◽  
Direct Costs ◽  
Cost Driver ◽  
Health Concern ◽  
The Past ◽  
Swedish Society ◽  
The Cost

AbstractBackgroundDepression is one of the most common causes of disability and is associated with substantial reductions in the individual's quality of life. The aim of this study was to estimate the economic burden of depression to Swedish society from 1997 to 2005.Materials and MethodsThe study was conducted in a cost-of-illness framework, measuring both the direct cost of providing health care to depressive patients, and the indirect costs as the value of production that is lost due to morbidity or mortality. The costs were estimated by a prevalence and top-down approach.ResultsThe cost of depression increased from a total of €1.7 billion in 1997 to €3.5 billion in 2005, representing a doubling of the burden of depression to society. The main reason for the cost increase is found in the significant increase in indirect costs due to sick leave and early retirement during the past decade, whereas direct costs were relatively stable over time. In 2005, indirect costs were estimated at €3 billion (86% of total costs) and direct costs at €500 million (16%). Cost of drugs was estimated at €100 million (3% of total cost).ConclusionThe cost of depression is substantial to society and the main cost driver is indirect costs due to sick leave and early retirement. The cost of depression has doubled during the past eight years making it a major public health concern for the individuals afflicted, carers and decision makers.

Sign in / Sign up

Export Citation Format

Share Document